Windlas Biotech Limited IPO
Windlas Biotech Limited was a mainboard IPO in the Pharmaceuticals sector, offered at ₹448–₹460 per share to raise ₹402 crore. The issue was subscribed 22.47× overall (QIBs 24.4×, NIIs 15.73×, retail 24.27×). It listed on 16 Aug 2021 at ₹437 and closed its first day at ₹407, a listing loss of -11.5% versus the ₹460 issue price. It now trades around ₹876 (+90.5% versus the issue price).
Frequently asked questions
- How many times was the Windlas Biotech Limited IPO subscribed?
- The Windlas Biotech Limited IPO was subscribed 22.47× overall — 24.4× in the QIB category, 15.73× among non-institutional investors, 24.27× in retail.
- What were the Windlas Biotech Limited IPO listing gains?
- Windlas Biotech Limited listed on 16 Aug 2021 at ₹437, closing its first day at ₹407 — a listing loss of -11.5% versus the ₹460 issue price.
- What were the retail allotment odds for the Windlas Biotech Limited IPO?
- Retail was subscribed 24.27×, so a single-lot application had roughly a 4.1% chance of allotment (about 1 in 24), and allotment was finalised on 10 Aug 2021.
- What was the price band and lot size of the Windlas Biotech Limited IPO?
- The price band was ₹448–₹460 per share, with a minimum lot of 30 shares (₹13,800 at the upper band).
- Who were the registrar and lead manager for the Windlas Biotech Limited IPO?
- Link Intime India Private Limited was the registrar, and SBI Capital Markets was the book-running lead manager.